Effect of topical application of diluted betadine and artificial tears, or betamethasone and chloramphenicol in epidemic keratoconjunctivitis.

Two Topical (diluted betadine and artificial tears) or (betamethasone and chloramphenicol) versus placebo (two drops of artificial tears) interventions to control clinical symptoms and complications of epidemic keratoconjunctivitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250308064985N1

Enrollment

Registered

2025-05-31

Start date

2025-06-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidemic keratoconjunctivitis. Keratoconjunctivitis due to adenovirus

Interventions

Intervention 1: Control group: Receives two Tearlose artificial tears (Sina Darou, Tehran). Intervention 2: Intervention group: Receives diluted betadine eye drop plus of artificial tears eye drop (S

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of epidemic viral conjunctivitis based on: Clinical symptoms (patient-reported): Redness, tearing, and foreign body sensation. Ophthalmologist-confirmed findings: Subconjunctival petechial hemorrhages, purulent discharge, and follicular formation. Willingness to participate in the study (informed consent)

Exclusion criteria

Exclusion criteria: History of prior treatment Hypersensitivity to iodine Pregnancy Presence of thyroid disorders

Design outcomes

Primary

Measure	Time frame
Ocular signs and symptoms on examination. Timepoint: Baseline, day 2, and week 2 post-intervention. Method of measurement: Ophthalmic examination.;Adverse effects. Timepoint: Baseline, day 2, and week 2 post-intervention. Method of measurement: Ophthalmic examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTaher Torabi

Zahedan University of Medical Sciences

T.torabi@zaums.ac.ir+98 54 3321 9917

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026